Information Provided By:
Fly News Breaks for January 15, 2016
SRPT
Jan 15, 2016 | 13:46 EDT
William Blair has lowered its price target on Sarepta to $29 from $60 to account for a lower expectation for success of eteplirsen based on the tone of the FDA briefing documents. The firm still assumes the launch of eteplirsen in the second half 2016, but said it will revisit that assumption following the FDA advisory panel. William Blair keeps an Outperform rating on Sarepta shares.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.